DOI QR코드

DOI QR Code

Bevacizumab Regulates Cancer Cell Migration by Activation of STAT3

  • Wu, Huan-Huan (Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology) ;
  • Zhang, Shuai (Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology) ;
  • Bian, Huan (Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology) ;
  • Li, Xiao-Xu (Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology) ;
  • Wang, Lin (Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology) ;
  • Pu, Yin-Fei (The Second Dental Center, Peking University School and Hospital of Stomatology) ;
  • Wang, Yi-Xiang (Central Laboratory, Peking University School and Hospital of Stomatology) ;
  • Guo, Chuan-Bin (Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology)
  • Published : 2015.10.06

Abstract

There are numerous clinical cases indicating that long-term use of bevacizumab may increase the invasiveness of tumors. However, to date, little is known about underlying molecular mechanisms. Therefore, the purpose of our study was to investigate effects of bevacizumab in four cancer cells lines (WSU-HN6, CAL27, Tca83, and HeLa). It was found to promote migration and invasion in the WSU-HN6 and Tca83 cases, while exerting inhibitory effects in CAL27 and HeLa cells. The signal transducer and activator of transcription (STAT) 3 inhibitors niclosamide and S3I-201 inhibited the STAT3 signal pathway, which is activated by bevacizumab. These inhibitors also substantially blocked bevacizumab-induced migration of WSU-HN6 and Tca83 cells. Bevacizumab upregulated interleukin (IL)-6 and phosphorylated (p)-STAT3 expression time-dependently. Therefore, we propose that bevacizumab has differential effects on the migration of different cancer cell lines and promotes migration via the IL-6/STAT3 signaling pathway.

Keywords

Bevacizumab;STAT3;migration;pathway inhibition;interleukin-6

Acknowledgement

Supported by : National Nature Science Foundation of China

References

  1. Carmeliet P, Jain RK (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature, 473, 298-307. https://doi.org/10.1038/nature10144
  2. Chen Z, Han ZC (2008). STAT3: a critical transcription activator in angiogenesis. Med Res Rev, 28, 185-200. https://doi.org/10.1002/med.20101
  3. Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007). FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist, 12, 713-8. https://doi.org/10.1634/theoncologist.12-6-713
  4. de Groot JF, Fuller G, Kumar AJ, et al (2010). Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice. Neuro Oncol, 12, 233-42. https://doi.org/10.1093/neuonc/nop027
  5. Desjardins A, Reardon DA, Herndon JN, et al (2008). Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res, 14, 7068-73. https://doi.org/10.1158/1078-0432.CCR-08-0260
  6. Duran AO, Karaca H, Besiroglu M, et al (2014). XELOX plus bevacizumab vs. FOLFIRI plus bevacizumab treatment for first-line chemotherapy in metastatic colon cancer: a retrospective study of the Anatolian Society of Medical Oncology. Asian Pac J Cancer Prev, 15, 10375-9.
  7. Furuta T, Nakada M, Misaki K, et al (2014). Molecular analysis of a recurrent glioblastoma treated with bevacizumab. Brain Tumor Pathol, 31, 32-9. https://doi.org/10.1007/s10014-013-0142-4
  8. Gao L, Li FS, Chen XH, et al (2014). Radiation induces phosphorylation of STAT3 in a dose- and time-dependent manner. Asian Pac J Cancer Prev, 15, 6161-4. https://doi.org/10.7314/APJCP.2014.15.15.6161
  9. Garcia AA, Hirte H, Fleming G, et al (2008). Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol, 26, 76-82. https://doi.org/10.1200/JCO.2007.12.1939
  10. Gil MJ, de Las PR, Reynes G, et al (2012). Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anticancer Drugs, 23, 659-65. https://doi.org/10.1097/CAD.0b013e3283534d3e
  11. Grivennikov S, Karin M (2008). Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell, 13, 7-9. https://doi.org/10.1016/j.ccr.2007.12.020
  12. Hainsworth JD, Shih KC, Shepard GC, et al (2012). Phase II study of concurrent radiation therapy, temozolomide, and bevacizumab followed by bevacizumab/everolimus as first-line treatment for patients with glioblastoma. Clin Adv Hematol Oncol, 10, 240-6.
  13. Hein M, Graver S (2013). Tumor cell response to bevacizumab single agent therapy in vitro. Cancer Cell Int, 13, 94. https://doi.org/10.1186/1475-2867-13-94
  14. Hurwitz H, Fehrenbacher L, Novotny W, et al (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350, 2335-42. https://doi.org/10.1056/NEJMoa032691
  15. Ishida J, Onishi M, Kurozumi K, et al (2014). Integrin inhibitor suppresses bevacizumab-induced glioma invasion. Transl Oncol, 7, 292-302. https://doi.org/10.1016/j.tranon.2014.02.016
  16. Iwamoto FM, Abrey LE, Beal K, et al (2009). Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurol, 73, 1200-6. https://doi.org/10.1212/WNL.0b013e3181bc0184
  17. Keating GM (2014). Bevacizumab: a review of its use in advanced cancer. Drugs, 74, 1891-925. https://doi.org/10.1007/s40265-014-0302-9
  18. Keunen O, Johansson M, Oudin A, et al (2011). Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma. Proc Natl Acad Sci U S A, 108, 3749-54. https://doi.org/10.1073/pnas.1014480108
  19. Lai A, Tran A, Nghiemphu PL, et al (2011). Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol, 29, 142-8. https://doi.org/10.1200/JCO.2010.30.2729
  20. Lucio-Eterovic AK, Piao Y, de Groot JF (2009). Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res, 15, 4589-99. https://doi.org/10.1158/1078-0432.CCR-09-0575
  21. Miletic H, Niclou SP, Johansson M, Bjerkvig R (2009). Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms. Expert Opin Ther Targets, 13, 455-68. https://doi.org/10.1517/14728220902806444
  22. Mrugala MM (2009). Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurol, 72, 773-4.
  23. Narayana A, Kelly P, Golfinos J, et al (2009). Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg, 110, 173-80. https://doi.org/10.3171/2008.4.17492
  24. Pandurangan AK, Esa NM (2014). Signal transducer and activator of transcription 3 - a promising target in colitisassociated cancer. Asian Pac J Cancer Prev, 15, 551-60. https://doi.org/10.7314/APJCP.2014.15.2.551
  25. Pan JX, Ding K, Wang CY (2012). Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer, 31, 178-84. https://doi.org/10.5732/cjc.011.10290
  26. Piao Y, Liang J, Holmes L, et al (2012). Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol, 14, 1379-92. https://doi.org/10.1093/neuonc/nos158
  27. Piao Y, Liang J, Holmes L, et al (2013). Acquired resistance to anti-VEGF therapy in glioblastoma is associated with a mesenchymal transition. Clin Cancer Res, 19, 4392-403. https://doi.org/10.1158/1078-0432.CCR-12-1557
  28. Sen M, Joyce S, Panahandeh M, et al (2012). Targeting Stat3 abrogates EGFR inhibitor resistance in cancer. Clin Cancer Res, 18, 4986-96. https://doi.org/10.1158/1078-0432.CCR-12-0792
  29. Shao H, Cheng HY, Cook RG, Tweardy DJ (2003). Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res, 63, 3923-30.
  30. Siddiquee K, Zhang S, Guida WC, et al (2007). Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A, 104, 7391-6. https://doi.org/10.1073/pnas.0609757104
  31. Simon T, Coquerel B, Petit A, et al (2014). Direct effect of bevacizumab on glioblastoma cell lines in vitro. Neuromolecular Med, 16, 752-71. https://doi.org/10.1007/s12017-014-8324-8
  32. Wang SW, Sun YM (2014). The IL-6/JAK/STAT3 pathway: potential therapeutic strategies in treating colorectal cancer (Review). Int J Oncol, 44, 1032-40.
  33. Wedam SB, Low JA, Yang SX, et al. (2006). Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol, 24, 769-77. https://doi.org/10.1200/JCO.2005.03.4645
  34. Willett CG, Boucher Y, di Tomaso E, et al (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med, 10, 145-7. https://doi.org/10.1038/nm988
  35. Yu CL, Meyer DJ, Campbell GS, et al (1995). Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. Science, 269, 81-3. https://doi.org/10.1126/science.7541555
  36. Zhou Y, Tian L, Zhang YC, et al (2014). Apoptotic effects of psiRNA-STAT3 on 4T1 breast cancer cells in vitro. Asian Pac J Cancer Prev, 15, 6977-82. https://doi.org/10.7314/APJCP.2014.15.16.6977

Cited by

  1. Cell culture models of oral mucosal barriers: A review with a focus on applications, culture conditions and barrier properties pp.2168-8370, 2018, https://doi.org/10.1080/21688370.2018.1479568